skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters

Abstract

Dose distributions for normal and tumor tissues from intraperitoneally administered radiolabeled antibodies have been calculated for 90-Yttrium (90Y), 131-Iodine (131I), and 211-Astatine (211At). The dose calculations use data on the activity of intraperitoneal fluid administered, the percent injected dose/gm uptake by tumor, biological half life, and a model for diffusion of antibody/radionuclide complex into peritoneal tissues. Calculations are performed for planar and hemispherical tumor shapes, ranging in size to establish the influence of geometry on dose distribution. Calculations for tumor geometry obtained from biopsies are also performed. When the activity is concentrated on or near the tumor surface, the maximum dose to a planar tumor for a 20 mci administration of 90Y is approximately 60 Gy, and falls rapidly to 50% of this value within 1 mm. However, for a hemispherical tumor, the dose is a maximum of 26 Gy, with an average of approximately 20 Gy. The surface dose from 131I (130 mci) is 240 Gy, and diminishes to 20 Gy in .05 cm in the planar case, whereas a hemispherical tumor receives a dose of 90 Gy over a large fraction of the volume, with the distal portions receiving 40 Gy. The surface dose for an administration ofmore » 70 mci of 211 At is 450 Gy and decreases to 50% of this value in 30 microns. Both surface geometry and tumor size are important determinants in the heterogeneity of tumor dose, as are the dose administered, antibody uptake, biodistribution, and residence time factors. These initial studies suggest that the size of disease which may be effectively treated is much less than the range of the particle emitted by radiolabeled antibodies. Furthermore, therapy is ultimately limited by the degree to which the antibody/radionuclide complex can diffuse and permeate the tumor.« less

Authors:
; ; ; ; ; ; ;  [1]
  1. Michael Reese/Univ. of Chicago, IL (USA)
Publication Date:
OSTI Identifier:
6246462
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics; (USA)
Additional Journal Information:
Journal Volume: 19:6; Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; NEOPLASMS; RADIOIMMUNOTHERAPY; PERITONEUM; RADIATION DOSE DISTRIBUTIONS; ASTATINE 211; BIOLOGICAL HALF-LIFE; CALCULATION METHODS; INTRAPERITONEAL INJECTION; IODINE 131; MONOCLONAL ANTIBODIES; RADIATION DOSES; YTTRIUM 90; ALPHA DECAY RADIOISOTOPES; ANTIBODIES; ASTATINE ISOTOPES; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; DAYS LIVING RADIOISOTOPES; DISEASES; DOSES; ELECTRON CAPTURE RADIOISOTOPES; HEAVY NUCLEI; HOURS LIVING RADIOISOTOPES; IMMUNOLOGY; IMMUNOTHERAPY; INJECTION; INTAKE; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; MEDICINE; MEMBRANES; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ODD-ODD NUCLEI; RADIOIMMUNOLOGY; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; SEROUS MEMBRANES; THERAPY; YTTRIUM ISOTOPES; 550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)

Citation Formats

Roeske, J C, Chen, G T, Atcher, R W, Pelizzari, C A, Rotmensch, J, Haraf, D, Montag, A, and Weichselbaum, R R. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. United States: N. p., 1990. Web. doi:10.1016/0360-3016(90)90370-Y.
Roeske, J C, Chen, G T, Atcher, R W, Pelizzari, C A, Rotmensch, J, Haraf, D, Montag, A, & Weichselbaum, R R. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. United States. https://doi.org/10.1016/0360-3016(90)90370-Y
Roeske, J C, Chen, G T, Atcher, R W, Pelizzari, C A, Rotmensch, J, Haraf, D, Montag, A, and Weichselbaum, R R. 1990. "Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters". United States. https://doi.org/10.1016/0360-3016(90)90370-Y.
@article{osti_6246462,
title = {Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters},
author = {Roeske, J C and Chen, G T and Atcher, R W and Pelizzari, C A and Rotmensch, J and Haraf, D and Montag, A and Weichselbaum, R R},
abstractNote = {Dose distributions for normal and tumor tissues from intraperitoneally administered radiolabeled antibodies have been calculated for 90-Yttrium (90Y), 131-Iodine (131I), and 211-Astatine (211At). The dose calculations use data on the activity of intraperitoneal fluid administered, the percent injected dose/gm uptake by tumor, biological half life, and a model for diffusion of antibody/radionuclide complex into peritoneal tissues. Calculations are performed for planar and hemispherical tumor shapes, ranging in size to establish the influence of geometry on dose distribution. Calculations for tumor geometry obtained from biopsies are also performed. When the activity is concentrated on or near the tumor surface, the maximum dose to a planar tumor for a 20 mci administration of 90Y is approximately 60 Gy, and falls rapidly to 50% of this value within 1 mm. However, for a hemispherical tumor, the dose is a maximum of 26 Gy, with an average of approximately 20 Gy. The surface dose from 131I (130 mci) is 240 Gy, and diminishes to 20 Gy in .05 cm in the planar case, whereas a hemispherical tumor receives a dose of 90 Gy over a large fraction of the volume, with the distal portions receiving 40 Gy. The surface dose for an administration of 70 mci of 211 At is 450 Gy and decreases to 50% of this value in 30 microns. Both surface geometry and tumor size are important determinants in the heterogeneity of tumor dose, as are the dose administered, antibody uptake, biodistribution, and residence time factors. These initial studies suggest that the size of disease which may be effectively treated is much less than the range of the particle emitted by radiolabeled antibodies. Furthermore, therapy is ultimately limited by the degree to which the antibody/radionuclide complex can diffuse and permeate the tumor.},
doi = {10.1016/0360-3016(90)90370-Y},
url = {https://www.osti.gov/biblio/6246462}, journal = {International Journal of Radiation Oncology, Biology and Physics; (USA)},
issn = {0360-3016},
number = ,
volume = 19:6,
place = {United States},
year = {Sat Dec 01 00:00:00 EST 1990},
month = {Sat Dec 01 00:00:00 EST 1990}
}